Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.78 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.68 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.59 |
| ▸ | IDO1 | P14902 | 2/20 | 0.56 |
| ▸ | AGXT | P21549 | 2/20 | 0.56 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.52 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22202237 | 1.00 | TAAR1 (1.00) | TAAR1HRH3LOXL2CYP2A6IDO1 | |
| SCHEMBL28208288 | 1.00 | TAAR1 (1.00) | TAAR1HRH3LOXL2CYP2A6IDO1 | |
| SCHEMBL22291708 | 1.00 | TAAR1 (1.00) | TAAR1HRH3LOXL2CYP2A6IDO1 | |
| Hydrochloric Acid SCHEMBL1661202 | 0.97 | TAAR1 (0.95) | TAAR1HRH3LOXL2CYP2A6IDO1 | |
| Hydrochloric Acid SCHEMBL7921699 | 0.97 | TAAR1 (0.95) | TAAR1HRH3LOXL2CYP2A6IDO1 | |
| SCHEMBL28164006 | 0.93 | TAAR1 (0.86) | TAAR1HRH3LOXL2CYP2A6IDO1 | |
| Biphenyl SCHEMBL27410798 | 0.92 | TAAR1 (0.84) | TAAR1HRH3LOXL2CYP2A6IDO1 | |
| SCHEMBL2274647 | 0.88 | HRH3 (1.00) | TAAR1HRH3LOXL2CYP2A6ADRB2 | |
| SCHEMBL5362598 | 0.87 | TAAR1 (0.77) | TAAR1HRH3LOXL2CYP2A6IDO1 | |
| SCHEMBL22462436 | 0.87 | TAAR1 (0.75) | TAAR1HRH3LOXL2CYP2A6IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122081969-A | VSe-Cu2-xSe nanosheet catalysis C (sp)3) -H bond CO2Method for directionally synthesizing alpha-hydroxy/amino acid by carboxylation | — | 2026-05-26 | — | — | CN | claimed |
| CN-115874288-B | Preparation method of zinc-based organic metal halide long afterglow material monocrystal and powder | 首都师范大学 | 2026-05-19 | — | — | CN | claimed |
| CN-118634745-B | Preparation method of microcapsule embedded with probiotics | 绍兴同创生物科技有限公司 | 2025-03-18 | — | — | CN | claimed |
| CN-117596783-B | High-frequency carbon-hydrogen copper-clad plate and preparation method thereof | 江苏耀鸿电子有限公司 | 2024-10-01 | — | — | CN | claimed |
| CN-118634745-A | Preparation method of microcapsule embedded with probiotics | 绍兴同创生物科技有限公司 | 2024-09-13 | — | — | CN | claimed |
| CN-118027102-A | Ruthenium complex with enaminone structure, and preparation method and application thereof | 中国科学院理化技术研究所 | 2024-05-14 | — | — | CN | claimed |
| CN-117596783-A | High-frequency carbon-hydrogen copper-clad plate and preparation method thereof | 江苏耀鸿电子有限公司 | 2024-02-23 | — | — | CN | claimed |
| CN-115874288-A | Preparation method of zinc-based organic metal halide long afterglow material single crystal and powder | 首都师范大学 | 2023-03-31 | — | — | CN | claimed |
| CN-108329225-B | P-dibenzoyl dimer derivative and synthetic method and application thereof | 北京大学 | 2021-03-09 | — | — | CN | claimed |
| CN-110669058-A | Tricyclic quinolone carboxylic acid and preparation method thereof | 江西农业大学 | 2020-01-10 | — | — | CN | claimed |
| EP-1545515-A1 | 3-PYRROLYL-PYRIDOPYRAZOLES AND 3-PYRROLYL-INDAZOLES AS NOVEL KINASE INHIBITORS | Sugen, Inc. (US) | 2005-06-29 | — | — | EP | claimed |
| EP-1372686-B1 | METHODS AND COMPOSITIONS FOR PEPTIDE SYNTHESIS | TRIMERIS INC (US) | 2005-02-02 | — | — | EP | claimed |
| WO-2004099127-A1 | NOVEL COMPOUNDS AS KINASE INHIBITORS | NOVO NORDISK A/S (DK) | 2004-11-18 | — | — | WO | claimed |
| US-20040092546-A1 | 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors | SUGEN, INC. | 2004-05-13 | — | — | US | claimed |
| WO-2004014368-A1 | 3-PYRROLYL-PYRIDOPYRAZOLES AND 3-PYRROLYL-INDAZOLES AS NOVEL KINASE INHIBITORS | SUGEN, INC. (US) | 2004-02-19 | — | — | WO | claimed |
| JP-2868313-B2 | — | — | 1999-03-10 | — | — | JP | claimed |
| EP-0454511-B1 | N-substituted heterocycle derivatives, their preparation, compositions containing them | SANOFI SA (FR) | 1998-06-17 | — | — | EP | claimed |
| EP-0532410-A1 | N-substituted heterocyclic derivatives as angiotensin II inhibitors | SANOFI (FR) | 1993-03-17 | — | — | EP | claimed |
| EP-0454511-A1 | N-substituted heterocycle derivatives, their preparation, compositions containing them | SANOFI (FR) | 1991-10-30 | — | — | EP | claimed |
| WO-1991014679-A1 | HETEROCYCLIC N-SUBSTITUTED DERIVATIVES, THEIR PREPARATION AND THEPHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI (FR) | 1991-10-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092546-A1 | 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors | MAP3K19, MAP3K1, MAP3K7 | TAAR1 3622/4885HRH3 2602/4885LOXL2 2185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.